Immunicum Receives FDA Orphan Drug Designation
Immunicum AB (publ; IMMU.ST) announced that it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the Company’s lead candidate, ilixadencel, a cell-based, off-the-shelf immune primer, for the